Multimedialna platforma wiedzy medycznej Internetowa Księgarnia Medyczna Kalendarium Konferencji
Endokrynologia Polska
MENU
Shortcuts Submit an article Author Guidelines Polish Society of Endocrinology Reviewers 2022 Redeem voucher Abstracts, 5–7 May 2022, Gliwice

open access

Vol 61, No 4 (2010)
Review paper
Submitted: 2013-02-15
Published online: 2010-08-31
View PDF Download PDF file
Get Citation

Chromogranin A (CgA) - the influence of various factors in vivo and in vitro, and existing disorders on it’s concentration in blood

Piotr Glinicki, Wojciech Jeske
DOI: 10.5603/ep.25370
·
Endokrynol Pol 2010;61(4):384-387.

open access

Vol 61, No 4 (2010)
Review Article
Submitted: 2013-02-15
Published online: 2010-08-31

Abstract

Chromogranin A (CgA) is regarded as a major, nonspecific neuroendocrine tumour (NET) marker. The results of CgA blood concentration, however, may actually be influenced by various factors or coexisting pathological conditions. Among the factors causing a substantial increase of the blood CgA concentration are: treatment with proton-pump inhibitors or H2 -receptor blockers, chronic atrophic gastritis (type A), impaired renal function, prostate cancer and BPH, and rheumatoid arthritis with high level of RF IgM. In addition, the sort of investigated biological material (whether it is serum or plasma) is of importance.
There are also many conditions which may have a moderate or little influence on the concentration of CgA, among them are: inflammatory bowel disease (ulcerative colitis and Crohn’s disease), deteriorating liver function, untreated essential hypertension, heart failure, hypercortisolism, pregnancy, and, in some subjects, ingestion of a meal.
Proper assessment of the CgA results requires detailed knowledge about various factors, drugs, and pathological conditions influencing its concentration in blood. (Pol J Endocrinol 2010; 61 (4): 384-387)

Abstract

Chromogranin A (CgA) is regarded as a major, nonspecific neuroendocrine tumour (NET) marker. The results of CgA blood concentration, however, may actually be influenced by various factors or coexisting pathological conditions. Among the factors causing a substantial increase of the blood CgA concentration are: treatment with proton-pump inhibitors or H2 -receptor blockers, chronic atrophic gastritis (type A), impaired renal function, prostate cancer and BPH, and rheumatoid arthritis with high level of RF IgM. In addition, the sort of investigated biological material (whether it is serum or plasma) is of importance.
There are also many conditions which may have a moderate or little influence on the concentration of CgA, among them are: inflammatory bowel disease (ulcerative colitis and Crohn’s disease), deteriorating liver function, untreated essential hypertension, heart failure, hypercortisolism, pregnancy, and, in some subjects, ingestion of a meal.
Proper assessment of the CgA results requires detailed knowledge about various factors, drugs, and pathological conditions influencing its concentration in blood. (Pol J Endocrinol 2010; 61 (4): 384-387)

Full Text:

View PDF Download PDF file
Get Citation

Keywords

chromogranin A; neuroendocrine tumours

About this article
Title

Chromogranin A (CgA) - the influence of various factors in vivo and in vitro, and existing disorders on it’s concentration in blood

Journal

Endokrynologia Polska

Issue

Vol 61, No 4 (2010)

Article type

Review paper

Pages

384-387

Published online

2010-08-31

Page views

598

Article views/downloads

3146

DOI

10.5603/ep.25370

Bibliographic record

Endokrynol Pol 2010;61(4):384-387.

Keywords

chromogranin A
neuroendocrine tumours

Authors

Piotr Glinicki
Wojciech Jeske

Regulations

Important: This website uses cookies. More >>

The cookies allow us to identify your computer and find out details about your last visit. They remembering whether you've visited the site before, so that you remain logged in - or to help us work out how many new website visitors we get each month. Most internet browsers accept cookies automatically, but you can change the settings of your browser to erase cookies or prevent automatic acceptance if you prefer.

Via MedicaWydawcą jest  VM Media Group sp. z o.o., Grupa Via Medica, ul. Świętokrzyska 73, 80–180 Gdańsk

tel.:+48 58 320 94 94, faks:+48 58 320 94 60, e-mail:  viamedica@viamedica.pl